An Assessment of Eligibility for Inhaled Insulin (Exubera) : the Fremantle Diabetes Study

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The product information ( 1 ) for human insulin inhalation powder (Exubera; Pfizer) recommends spirometry at baseline, 6 months postinitiation, and at least annually thereafter. Patients with a forced expiratory volume in the first second (FEV 1)
Original languageEnglish
Pages (from-to)360-361
JournalDiabetes Care
Volume30
Issue number2
DOIs
Publication statusPublished - 2007

Fingerprint Dive into the research topics of 'An Assessment of Eligibility for Inhaled Insulin (Exubera) : the Fremantle Diabetes Study'. Together they form a unique fingerprint.

Cite this